The abstract is read at the publisher; the summary is JClub's.
Ritlecitinib targets JAK3/TEC-family kinase activity in non-segmental vitiligo, reducing T-cell activation and melanocyte killing in vitro and in autologous skin explants.
- Why it matters: Relapse after broad JAK inhibition may reflect persistent JAK3/IL-15-dependent T-cell programs, but ritlecitinib’s mechanism in vitiligo is not well defined.
- What they did: The authors integrated scRNAseq and multiplex immunohistochemistry to map JAK3/TEC-family kinase expression in vitiligo skin, then tested ritlecitinib on T-cell activation and melanocyte killing in vitro and in a proof-of-concept autologous human skin explant model.
- The result: Vitiligo lesions showed increased JAK3/TEC-family kinase-expressing cells, with strong TEC in keratinocytes and immune clusters near the epidermis, and ritlecitinib suppressed key pathogenic functions, supporting repigmentation therapy potential.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.